By Mill Chart
Last update: Dec 26, 2023
Consider GENMAB A/S -SP ADR (NASDAQ:GMAB) as an affordable growth stock, identified by our stock screening tool. NASDAQ:GMAB is showcasing impressive growth figures and is well-positioned in terms of profitability, solvency, and liquidity. Moreover, it seems to be priced reasonably. Let's dive deeper into the analysis.
A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:GMAB has received a 7 out of 10:
ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:GMAB was assigned a score of 5 for valuation:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:GMAB has earned a 8 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:GMAB has achieved a 7:
Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.
Check the latest full fundamental report of GMAB for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
GENMAB A/S -SP ADR
NASDAQ:GMAB (4/23/2024, 4:01:25 PM)
After market: 29.0366 +0.48 (+1.67%)28.56
-0.41 (-1.42%)
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Genmab is buying a privately held company focused on antibody drug conjugates.
Genmab (GMAB) and AbbVie (ABBV) win FDA priority review for a marketing application to expand the label for their bispecific antibody epcoritamab-bysp. Read more here.
BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term
Genmab reports a FY operating profit of DKK 5,321 million in 2023, with revenue reaching DKK 16.47B, driven by successful collaborations and strong product...
Pfizer (PFE) and Genmab (GMAB) announced on Friday the marketing application for its cervical cancer antibody-drug conjugate ((ADC)) has been validated for revi